EGFR and non-small cell lung carcinoma: FASN was also reported to play a role in the acquisition of resistance to EGFR TKIs in EGFR-mutated NSCLC; the underlying mechanism involved an FASN-mediated palmitoylation of mutant EGFR, which conferred persistent activity to the receptor.